Myocardial infarction induced by penpulimab and anlotinib:a case report
10.12173/j.issn.1005-0698.202408099
- VernacularTitle:派安普利单抗联用安罗替尼致心肌梗死1例
- Author:
Chunhui WANG
1
;
Mengfei JIANG
;
Wei WU
;
Yuhong ZHOU
Author Information
1. 复旦大学附属中山医院药剂科(上海 200032)
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitor;
Tyrosine kinase inhibitor;
Myocardial infarction;
Adverse drug reaction
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(2):231-235
- CountryChina
- Language:Chinese
-
Abstract:
A 71-year-old man with undifferentiated sarcoma was treated with palliative first-line regimen(epirubicin,anlotinib and penpulimab)for 6 cycles and maintained with anlotinib and penpulimab for 30 cycles.He was admitted to the hospital due to chest pain 25 months after the first treatment.The laboratory examination showed cardiac troponin T 1.26 ng·mL-1,N terminal pro B type natriuretic peptide 8,545 pg·mL-1,coronary computed tomography angiography(CTA)showed non-calcified plaque in the left proximal anterior descending branch,severe lumen stenosis,nearly complete occlusion.Emergency CTA was performed on the same day,showing 50％stenosis of the distal left main coronary artery(LMCA);95％stenosis of the left anterior descending(LAD)branch ostium,the LAD branch was medium-sized and showed no stenosis;50％stenosis of the left circumflex branch(LCx),and a cardiac stent was implanted into the LAD branch.The patient has recovered after coronary artery stent implantation.Naranjo's Assessment Scale was used to evaluate the association of suspected drugs,the acute myocardial infarction of this patient was likely associated with the combination of penpulimab and anlotinib.Myocardial infarction is a rare but severe adverse drug reaction of anti-tumor treatment.This article summarizes the related risks and treatment measures to provide a reference for clinical medication safety.
